In this webinar our expert speaker, Anna Kerins, will explore how gut bacteria influence drug metabolism and the potential for toxic compound release.
In addition, Anna will discuss the critical role of gut bacterial β-glucuronidase (GUS) and how inhibiting GUS enzymes can reduce gut toxicity, improve patient outcomes, and enable higher drug doses. The session, hosted by Technology Networks, will highlight in vitro and in vivo studies of two GUS inhibitors, demonstrating their efficacy in preventing gut damage across species.
